

Serial No. 09/943,138
Response to Office Action
Page 2 of 12

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A mechanically stable biphasic injectable soft tissue augmentation composition comprising,
biocompatible micronized textured high density polyethylene particles having a size greater than sixty microns, and
a physiological carrier, wherein the composition is injected into soft tissue.
2. (Canceled)
3. (Canceled)
4. (Currently Amended) The composition of Claim 1, wherein the physiological carrier is ~~selected from~~ polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.
5. (Canceled)
6. (Canceled)
7. (Previously Presented) The composition of Claim 1, wherein the physiological carrier is polyvinylpyrrolidone.
8. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

Serial No. 09/943,138
Response to Office Action
Page 3 of 12

9. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

10. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

11. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.

12. (Canceled)

13. (Currently Amended) The composition of Claim 1 wherein the biocompatible micronized textured high density polyethylene and the physiological carrier are combined at a ratio of approximately 3:2 physiological carrier to biocompatible micronized textured high density polyethylene by weight.

14. (Canceled)

15. (Currently Amended) A method for soft tissue augmentation comprising, injecting into soft tissue, a mechanically stable biphasic injectable composition comprising,

biocompatible micronized textured high density polyethylene particles having a size greater than sixty microns, and
a physiological carrier.

16. (Cancelled)

1530838

Serial No. 09/943,138
Response to Office Action
Page 4 of 12

17. (Currently Amended) The method of Claim 15, wherein the physiological carrier is ~~selected from~~ polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.

18. (Previously Presented) The method of Claim 15, wherein injecting comprises, inserting a delivery apparatus containing the mechanically stable biphasic injectable composition into the injection site.

19. (Previously Presented) The method of Claim 15, wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.

20. (Currently Amended) The composition of Claim 1, wherein the biocompatible micronized textured high density polyethylene particles have a size greater than eighty microns.

21. (Currently Amended) The composition of Claim 1, wherein the biocompatible micronized textured high density polyethylene particles have a size greater than one-hundred microns.

22. (Currently Amended) A mechanically stable biphasic injectable soft tissue augmentation composition comprising,

biocompatible micronized textured high density polyethylene particles having a size of greater than sixty microns; and

a physiological carrier comprising polyvinylpyrrolidone, wherein the composition is injected into soft tissue.

1530838

Serial No. 09/943,138
Response to Office Action
Page 5 of 12

23. (Currently Amended) The composition of Claim 22 wherein the biocompatible micronized textured high density polyethylene and the physiological carrier are combined at a ratio of approximately 3:2 physiological carrier to biocompatible micronized textured high density polyethylene by weight.

24. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

25. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

26. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

27. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value of 17.

28. (Currently Amended) The composition of Claim 22, wherein the biocompatible micronized textured high density polyethylene particles have a size greater than eighty microns.

29. (Currently Amended) The composition of Claim 22, wherein the biocompatible micronized textured high density polyethylene particles have a size greater than one-hundred microns.